Mlp Saglik Hizmetleri As Class B · BIST:MPARK
Mlp Saglik Hizmetleri As Class B — MLP Care — 9M 2024 Earnings Presentation
20 slides from Mlp Saglik Hizmetleri As Class B's earnings presentation, Nov 12, 2024
Slide 1: MLPCARE 9M 2024 Presentation
MLPCARE 9M 2024 PRESENTATION N o v e m b e r 1 2 th, 2 0 2 4
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain certain forward-looking statements concerning MLP Care’s future performance and should be considered as good faith estimates made by the Company. These forward-looking statements reflect management expectations and are based upon currently ava
Slide 3: Muharrem Usta, Chairman & CEO
MUHARREM USTA CHAIRMAN & CEO
Slide 4: Q3 2024 Financials at a Glance
Q3 2024 Financials at a Glance Revenue EBITDA • Strong growth in both top and bottom line TL 9,782 m TL 2,620 m 27% Growth 38% Growth • Revenues supported by the private 9M 2024: 9M 2024: 26% Growth 37% Growth medical insurance • EBITDA growth on the back of disciplined cost management Net Debt / Ne
Slide 5: MLP Care Continues to Grow
MLP Care Continues to Grow 2024 New Hospitals Bed Capacity Square Meters Consolidation Capacity Starting From +6.300 Bed MP İncek - Ankara 182 8.225 May, 2024 MP İzmir 143 12.500 June, 2024 10% MP Gebze - Kocaeli 100 18.000 July, 2024 MP Ataşehir – İstanbul 80 8.000 July, 2024 MP Kosova - Pristina 8
Slide 6: Burcu Öztürk, CFO
Slide 7: Revenue Is up by 26%
Revenue Is up by 26% Revenue (TLm) 26.0% 27.570 21.880 26.9% 9.782 7.709 Q3 2023 Q3 2024 9M 2023 9M 2024 Denotes growth of Revenue vs. the same period of the last year 7
Slide 8: PMI & Top-up Insurance Lead Growth
PMI & Top-up Insurance Lead Growth 9M 2024 34% 24% SSI coverage allows us to reach the 7% 3% majority of Turkish population 14% 11% Self pay increases via premium service offering and elective procedures PMI, Top-up & Contracted Institutions market share grows rapidly on the back of strong gro
Slide 9: Continued Improvement in Average Prices
Continued Improvement in Average Prices Outpatient Revenues (TLm) Inpatient Revenues (TLm) 35.7% 28.2% 21.4% 14.6% 14.3% 13.6% Average Revenue Per Visit (ARPV) Average Revenue Per Protocol (ARPP) 16.263 3.222 2.654 14.191 9M 2023 9M 2024 9M 2023 9M 2024 ARPV 9M 2024: ARPP 9M 2024: 21.4% 14.6% Inpa
Slide 10: EBITDA Is Up By 37%
EBITDA Is Up By 37% EBITDA (TLm)1 37.1% 25.7% 7.088 23.6% 37.9% 5.169 26.8% 24.7% 2.620 1.900 Q3 2023 Q3 2024 9M 2023 9M 2024 1 EBITDA and EBITDA margin calculated by deducting general administrative expenses from gross profit and adding depreciation and amortization expenses Denotes growth of EBITD
Slide 11: Prudent Cost Management
Prudent Cost Management Cost of Service and G&A Expenses as a % of Revenues Cost Saving Measures enables us to reach the favourable EBITDA Margin EBITDA Margin 23.6% 25.7% Material costs as a % of revenue decreased by 12,1% 9,6% 86bps due to effective inventory management 6,2% 6,1% Doctor costs
Slide 12: Bottom Line Improves on The Back of Strong Operations
Bottom Line Improves on The Back of Strong Operations Net Profit (TLm) Net Profit (TLm) Allocated to Equity Holders of the Parent 44.8% 37.4% 4.445 4.042 82.3% 3.071 77.7% 2.942 2.207 2.091 1.211 1.177 Q3 2023 Q3 2024 9M 2023 9M 2024 Q3 2023 Q3 2024 9M 2023 9M 2024 Denotes growth of Net Profit and N
Slide 13: Leverage Ratio Improves
Leverage Leverage Ratio Ratio Improves Improves Total Debt Total Debt Breakdown 9M 2024 Other; 348 Bank 8.227 Loans; 1.527 7.168 Lease Liabilities ; 3.291 Bonds; 2.000 2023 9M 2024 Net Debt Net Debt excl. IFRS 16 4.406 3.777 1.600 1.334 0.6x 1.100 0.4x 0.2x 600 486 0.0x 2023 9M 2024 100 2023 9M 2024
Slide 14: Cash Flow
Cash Flow Operating Cash Flow increased million TL 9M 2023 9M 2024 Change due to robust EBITDA growth and EBITDA 5,169 7,088 1,919 positive working capital. Changes in working capital 1,005 1,467 462 Free Cash Flow increased due to Tax paid (272) (548) (276) increase in operating cash flow Other
Slide 15: Q&A
Q&A
Slide 16: Closing Remarks
Closing Remarks MUHARREM USTA CHAIRMAN & CEO
Slide 17: Thank You!
Thank You! MLP Care Investor Relations Deniz Can Yücel +90 212 227 5555 (Ext: 1148) deniz.yucel@mlpcare.com http://investor.mlpcare.com/en/
Slide 18: Historical Balance Sheet
Historical Balance Sheet Unaudited Audited TLm September 30, 2024 December 31, 2023 Cash and cash equivalents 3,392 3,821 Trade receivables 5,831 4,969 Inventory 973 1,463 Short term other assets 1,252 1,241 Current assets 11,448 11,493 Tangible and intangible fixed assets 15,477 11,356 Right of use
Slide 19: Historical P&L Statements
Historical P&L Statements Unaudited Unaudited Unaudited Unaudited Change (%) Change (%) TLm 9M 2024 9M 2023 Q3 2024 Q3 2023 Revenues 27,570 21,880 %26.0 9,782 7,709 %26.9 Cost of service (-) (20,099) (16,014) %25.5 (6,852) (5,478) %25.1 Gross profit 7,470 5,866 %27.4 2,930 2,230 %31.4 General admini
Slide 20: EBITDA Reconciliation
EBITDA Reconciliation Change Change TLm 9M 2024 9M 2023 (%) Q3 2024 Q3 2023 (%) Revenue 27,570 21,880 26.0% 9,782 7,709 26.0% Cost of service (20,099) (16,014) 25.5% (6,852) (5,478) 25.1% Gross profit 7,470 5,866 27.4% 2,930 2,230 31.4% General administrative expenses (-) (2,297) (2,168) 5.9% (839)